Pregnancy in renal transplant recipients: the Christchurch experience.
OBJECTIVE
Assess the pregnancies of our female renal transplant recipients and to document long term maternal and fetal outcome.


METHODS
Between 7 June 1972 and 31 December 1992 112 females had at least one renal transplant. Sixty-four of these 112 women were in the reproductive age and had a functioning graft.


RESULTS
Nine women had 16 pregnancies which resulted in 11 live births and three first trimester abortions. Two unplanned pregnancies were terminated. Mean age at transplantation was 17.2 yr [range 16-22.5 yr] and mean interval from transplant to pregnancy was 6.8 yr [range 1.8-9.0 yr]. Prednisone and azathioprine were used in all patients and cyclosporin in five. For seven of the successful pregnancies plasma creatinine remained < or = 0.10 mmol/L. One of these women developed allograft nephropathy 5 years after delivery and returned to dialysis 9 years later. For the other four successful pregnancies the preconception plasma creatinine was 0.12-0.14 mmol/L. The woman with two successful pregnancies had a halving of glomerular filtration rate during the second pregnancy, but it has remained stable for 15 years; one was poorly compliant with her immunosuppressive regimen and reached endstage renal failure two years after delivery; one developed cyclosporin nephrotoxicity, but 18 months later renal function was stable after a dosage reduction. Ten infants were delivered by caesarean section, four of them urgently. Three babies were preterm and five growth retarded. One died of sudden infant death syndrome at four months. All other infants developed normally.


CONCLUSIONS
There is no contraindication to pregnancy in female transplant recipients who have stable graft function and controlled blood pressure. Management of such pregnancies should be by shared obstetrical/nephrological/paediatric care.
Wong
K M
KM
Department of Nephrology, Christchurch Hospital.
Bailey
R R
RR
Lynn
K L
KL
Robson
R A
RA
Abbott
G D
GD
D000293:Adolescent; D000328:Adult; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007231:Infant, Newborn; D016030:Kidney Transplantation; D008875:Middle Aged; D009520:New Zealand; D011247:Pregnancy / Q000097:blood; D011256:Pregnancy Outcome
D016572:Cyclosporine; D003404:Creatinine